Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome

Fertility and Sterility

Volumn 91, Issue 1, 2009, Pages 213-219

  Wu, Yuwen ^a   Zhang, Jianhua ^a   Wen, Yu ^a   Wang, Hongwei ^a   Zhang, Muxun ^a   Cianflone, Katherine ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Adipokines; C reactive protein; insulin resistance; plasma lipids; polycystic ovary syndrome

Indexed keywords

ACYLATION STIMULATING PROTEIN; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHINA; COMPLEMENT C3; FATTY ACIDS, NONESTERIFIED; FEMALE; HIRSUTISM; HUMANS; INSULIN; LIPIDS; MENSTRUAL CYCLE; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; TRIGLYCERIDES; YOUNG ADULT;

EID: 57849083642     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.11.031     Document Type: Article

References (54)

1. Carmina E., Rosato F., Janno A., Rizzo M., and Longo R.A. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 91 (2006) 2-6
2. Dunaif A., and Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 52 (2001) 401-419
3. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
4. Laven J.S., Imani B., Eijkemans M.J., and Fauser B.C. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 57 (2002) 755-767
5. Kirchengast S., and Huber J. Body composition characteristics and fat distribution patterns in young infertile women. Fertil Steril 81 (2004) 539-544
6. Silfen M.E., Denburg M.R., Manibo A.M., Lobo R.A., Jaffe R., Ferin M., et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 88 (2003) 4682-4688
7. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
8. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., and Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
9. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
10. Wild S., Pierpoint T., McKeigue P., and Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52 (2000) 595-600
11. Wild R.A. Long-term health consequences of PCOS. Hum Reprod Update 8 (2002) 231-241
12. Robinson S., Henderson A.D., Gelding S.V., Kiddy D., Niththyananthan R., Bush A., et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 44 (1996) 277-284
13. Talbott E., Clerici A., Berga S.L., Kuller L., Guzick D., Detre K., et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51 (1998) 415-422
14. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
15. Pirwany I.R., Fleming R., Greer I.A., Packard C.J., and Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 54 (2001) 447-453
16. Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
17. Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K., et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (2001) 1410-1415
18. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
19. Park R., Detrano R., Xiang M., Fu P., Ibrahim Y., LaBree L., et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation 106 (2002) 2073-2077
20. Straub R.H., Hense H.W., Andus T., Scholmerich J., Riegger G.A., and Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 85 (2000) 1340-1344
21. Lagrand W.K., Visser C.A., Hermens W.T., Niessen H.W., Verheugt F.W., Wolbink G.J., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 100 (1999) 96-102
22. Bhakdi S., Torzewski M., Klouche M., and Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19 (1999) 2348-2354
23. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
24. Mikkola T.S., and Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53 (2002) 605-619
25. Kelly C.C., Lyall H., Petrie J.R., Gould G.W., Connell J.M., and Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 2453-2455
26. Tarkun I., Arslan B.C., Canturk Z., Turemen E., Sahin T., and Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89 (2004) 5592-5596
27. Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis I., Paterakis T., et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 36 (2006) 691-697
28. Topcu S., Caliskan M., Ozcimen E.E., Tok D., Uckuyu A., Erdogan D., et al. Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease?. Hum Reprod 21 (2006) 930-935
29. Meyer C., McGrath B.P., and Teede H.J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90 (2005) 5711-5716
30. Cianflone K.M., Sniderman A.D., Walsh M.J., Vu H.T., Gagnon J., and Rodriguez M.A. Purification and characterization of acylation stimulating protein. J Biol Chem 264 (1989) 426-430
31. Baldo A., Sniderman A.D., St-Luce S., Avramoglu R.K., Maslowska M., Hoang B., et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 92 (1993) 1543-1547
32. Cianflone K., Xia Z., and Chen L.Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609 (2003) 127-143
33. Yang Y., Lu H.L., Zhang J., Yu H.Y., Wang H.W., Zhang M.X., et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond) 30 (2006) 439-446
34. Cianflone K., Lu H., Smith J., Yu W., and Wang H. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin Endocrinol (Oxf) 62 (2005) 567-572
35. Muscari A., Massarelli G., Bastagli L., Poggiopollini G., Tomassetti V., Volta U., et al. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 53 (1998) 345-354
36. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
37. Saleh J., Summers L.K., Cianflone K., Fielding B.A., Sniderman A.D., and Frayn K.N. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 39 (1998) 884-891
38. Kalant D., Phelis S., Fielding B.A., Frayn K.N., Cianflone K., and Sniderman A.D. Increased postprandial fatty acid trapping in subcutaneouss adipose tissue in obese women. J Lipid Res 41 (2000) 1963-1968
39. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
40. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment (2000), World Health Organization, Geneva, Switzerland:
41. Kotler D.P., Ionescu G., Johnson J.A., Inada Y., He Q., Engelson E.S., et al. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 37 Suppl 2 (2003) S47-S51
42. Barutcuoglu B., Bozdemir A.E., Dereli D., Parildar Z., Mutaf M.I., Ozmen D., et al. Increased serum neopterin levels in women with polycystic ovary syndrome. Ann Clin Lab Sci 36 (2006) 267-272
43. Gonzalez F., Thusu K., Abdel-Rahman E., Prabhala A., Tomani M., and Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 48 (1999) 437-441
44. Amato G., Conte M., Mazziotti G., Lalli E., Vitolo G., Tucker A.T., et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 101 (2003) 1177-1182
45. Jeong W.K., Jeong M.H., Kim K.H., Lee S.R., Park O.Y., Yum J.H., et al. An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention. Korean J Intern Med 18 (2003) 154-160
46. Tamakoshi K., Yatsuya H., Kondo T., Hori Y., Ishikawa M., Zhang H., et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 27 (2003) 443-449
47. Weyer C., Tataranni P.A., and Pratley R.E. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 23 (2000) 779-785
48. Koistinen H.A., Vidal H., Karonen S.L., Dusserre E., Vallier P., Koivisto V.A., et al. Plasma acylation stimulating protein concentratiosn and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 21 (2001) 1034-1039
49. Ebeling P., Teppo A.M., Koistinen H.A., and Koivisto V.A. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 50 (2001) 283-287
50. Charlesworth J.A., Peake P.W., Campbell L.V., Pussell B.A., O'Grady S., and Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obes Relat Metab Disord 22 (1998) 1096-1102
51. Fujita T., Fujioka T., Murakami T., Satomura A., Fuke Y., and Matsumoto K. Chylomicron accelerates C3 tick-over by regulating the role of Factor H, leading to overproduction of acylation stimulating protein. J Clin Lab Anal 21 (2007) 14-23
52. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
53. Kalant D., Maslowska M., Scantlebury T., Wang H., and Cianflone K. Control of lipogenesis in adipose tissue and the role of acylation stimulating protein. Can J Diab 27 (2003) 154-171
54. Cianflone K., Zakarian R., Couillard C., Delplanque B., Despres J.P., and Sniderman A. Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J Lipid Res 45 (2004) 124-131